Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation — Thomas G. Martin (2022) | RDL Network
Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation
Thomas G. Martin, Marcelo Capra, Mohamad Mohty, Kenshi Suzuki, Hang Quach, Michèle Cavo, Philippe Moreau, Meletios A Dimopoulos, Kwee Yong, Christina Tekle, Meredith C. Foster, Yvonne Barnes, Marie‐Laure Risse, Joseph Mıkhael
Marcelo Capra, Thomas G. Martin, Philippe Moreau, Ross Baker, Luděk Pour, Chang‐Ki Min, Xavier Leleu, Mohamad Mohty, Marta Reinoso Segura, Mehmet Turgut, Richard LeBlanc, Marie‐Laure Risse, Laure Malinge, Sandrine Schwab, Meletios A Dimopoulos
Marcelo Capra, Thomas G. Martin, Philippe Moreau, Ross Baker, Luděk Pour, Chang‐Ki Min, Xavier Leleu, Mohamad Mohty, Marta Reinoso Segura, Mehmet Turgut, Richard LeBlanc, Marie‐Laure Risse, Laure Malinge, Sandrine Schwab, Meletios A Dimopoulos
Ecenur Guder Arslan, Kwee Yong, T. John Martin, Meletios A Dimopoulos, Joseph Mıkhael, Marcelo Capra, Thierry Façon, Roman Hájek, Ivan Špıčka, Ross Baker, Kihyun Kım, Gracia Martínez, Chang‐Ki Min, Philippe Moreau
Roman Hájek, Philippe Moreau, Bradley Augustson, Nelson Castro, Tomáš Pika, Sosana Delimpasi, Javier de la Rubia, Ângelo Maiolino, Tony Reiman, I. V. Kryuchkova, Joaquín Martínez‐López, Thomas G. Martin, Joseph Mıkhael, Kwee Yong, Marie‐Laure Risse, Gaëlle Asset, Sylvia Marion, Meletios A Dimopoulos
Discussion(0)
No comments yet. Be the first to comment.